




The relative strengths and weaknesses of Sucampo Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sucampo Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Sucampo Pharmaceuticals Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 224%, being 3.7% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	92,914
Cost of Goods Sold	0
Intangible Assets	7,415
Liabilities, Current	40,071
Liabilities, Non-Current	1,253
Other Assets	25,927
Other Compr. Net Income	-1,688
Other Expenses	24,637
Other Liabilities	43,442
Other Net Income	-565
Other Revenues	81,487
Property and Equipment	1,540
Research and Development	21,292
Selling, General and Administrative Expense	30,157

Output Variable	Value in 1000 USD
Assets	127,796
Liabilities	84,766
Expenses	76,086
Revenues	81,487
Stockholders Equity	43,030
Net Income	4,836
Comprehensive Net Income	3,992
BaseVar	186,194
ECR before Limited Liability	92%
Economic Capital Ratio	224%